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Abstract: Stronger Neo-Minophagen C (SNMC) is a glycyrrhizin-containing preparation that is approved in Japan for the 
treatment of chronic hepatic diseases and is marketed in Japan, China, Korea, Taiwan, and India. Glycyrrhizin, a triterpene 
present in the roots and rhizomes of licorice (Glycyrrhiza glabra) has been shown to have anti-infl  ammatory, anti-oxidative, 
and anti-viral eff  ects. In the present study, we demonstrated the marked neuroprotective eff  ects of SNMC in the postischemic 
rat brain aft  er middle cerebral artery occlusion (MCAO). We used 1 ml/kg of SNMC, which is within the dose range used for 
the treatment of patients with chronic hepatic disease. Th   e administration of SNMC intravenously at 30 minutes before or 30 
minutes and 3 hours aft  er MCAO (60 minutes) reduces mean infarct volumes to 27.0±4.2%, 37.1±12.4%, and 67.8±5.8% of 
that of untreated controls, respectively. This neuroprotective effect is accompanied by improvements in motor impairment 
and neurological defi  cits. Th   e administration of SNMC is shown to suppress microglia activation and neutrophil infi  ltration 
in the postischemic brain. In addition, SNMC suppresses lipopolysaccharide-induced nitrite production and proinfl  ammatory 
cytokine induction in a microglia cell line, BV2. Th   is indicates that the neuroprotective eff  ect of SNMC might be due, at least 
in part, to an anti-inflammatiory effect. Interestingly, SNMC shows significantly higher neuroprotective potency compared 
to an equivalent dose of pure glycyrrhizin, in terms of reducing infarct volume and improving neurological defi  cits. Together 
these results indicate that SNMC, a glycyrrhizin-containing preparation developed for chronic liver disease, has a marked 
neuroprotective function in the postischemic brain via its anti-infl  ammatory eff  ects.
Key words: Glycyrrhizic acid, Stronger Neo-Minophagen C, Middle cerebral artery infarction, Neuroprotection, Anti-
infl  ammation 
Received November 11, 2011; Revised December 5, 2011; Accepted December 5, 2011
Excitotoxicity and Zn
+2 toxicity play a key role in acute and 
massive neuronal death in the ischemic core [1]. This acute 
neuronal damage is followed by a second round of neu  ro-
nal injury in the surrounding regions, referred to as delayed 
neuronal death [2]. Postischemic infl  ammation and apoptosis, 
which may happen from a few hours to days aft  er the primary 
ischemic event, are shown to be associated with the delayed 
injury [3].
Stronger Neo-Minophagen C (SNMC) is a glycyrrhizin-
con  taining preparation that is approved in Japan for the 
treatment of chronic hepatic diseases and is marketed in 
Introduction
Cerebral ischemia leads to brain injury via a complex 
series of pathophysiological events that ultimately result in 
neuronal death and subsequent neurological dysfunction. Neuroprotection by glycyrrhizin-containing SNMC 
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Japan, China, Korea, Taiwan, and India [4]. It is available as 
a parenteral formulation (intravenous administration), and 
one ampoule (20 ml) contains 40 mg of glycyrrhizin, 20 mg 
of L-cystein, and 400 mg of glycine in a physiologic solution. 
Two amino acids are added to reduce the side effects of 
glycyrrhizin. A recent European randomized trial showed the 
biochemical eff  ects of a 26-week treatment with SNMC (100 
ml daily) in patients with chronic hepatitis C [5]. In addition, 
Arase et al. [6] demonstrated that long-term usage of SNMC 
(100 ml daily) is effective in preventing hepatocellular car-
cinoma (HCC) development in Japanese patients with chronic 
hepatitis C. Various mechanisms by which SNMC prevents 
disease progression of chronic hepatitis C have been reported.
Glycyrrhizin is present in large quantities in the roots and 
rhizomes of licorice (Glycyrrhiza glabra) and is composed of a 
molecule of glycyrrhizic acid and two molecules of glucuronic 
acid. This natural triterpene has been used clinically due to 
its anti-infl  ammatory, anti-allergic, and anti-viral eff  ects [7]. 
Glycyrrhizin has been used in the treatment of patients with 
chronic hepatitis B and C [8, 9]. In addition, glycyrrhizin 
reduces ischemia/reperfusion-induced liver injury [10] and 
attenuates N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) neurotoxicity in mice and MPP
+-induced cell 
death in PC12 cells [11]. Further, Hwang et al. [12] reported 
on the neuroprotective effects of roasted licorice on gerbil 
hippocampi aft  er transient forebrain ischemia. 
In the present study, we investigate the neuroprotective 
effects of SNMC in the postischemic rat brain after middle 
cerebral artery occlusion (MCAO), and seek to elucidate the 
molecular mechanism responsible for its neuroprotective 
eff  ects. It is found that SNMC aff  ords robust neuroprotection 
in the postischemic brain, and that these eff  ects are, at least in 
part, attributable to an anti-infl  ammatory eff  ect.
Materials and Methods
Animals
Male Sprague-Dawley rats (Th   e Orient Co., Seoul, Korea) 
were used throughout this experiment, and randomly assig-
ned to SNMC- and glycyrrhizin-treated or vehicle (phosphate 
buff  ered saline [PBS])-treated control groups. At the start of 
the experiment, animals were weighed at 280-320 g (10-week-
old) and were housed separately under a 12 : 12 hour light : 
dark cycle with free access to food and water. 
Surgical procedure for MCA occlusion
All animal experiments were carried out in accordance 
with “The Guidelines for Animal Research” issued by Inha 
University School of Medicine. MCAO is carried out as 
pre  viously described [13]. In brief, male Sprague-Dawley 
rats (250-300 g) were anesthetized with 5% isoflurane in a 
30% oxygen/70% nitrous oxide gas mixture; anesthesia was 
maintained using 0.5% isoflurane in the same gas mixture 
throughout the procedure. MCAO was maintained for 1 hour 
using a nylon suture, and this was followed by reperfusion for 
12 hours to 14 days. The left femoral artery was cannulated 
during the procedure to obtain blood samples as well as to 
monitor pH, PaO2, PaCO2, and blood glucose concentration 
(I-STAT, Sensor Devises, Waukesha, WI, USA). Regional 
cere  bral blood flow was monitored using a laser Doppler 
fl  owmeter (Perifl  ux System 5000, Perimed, Jarfalla, Sweden). 
A thermo-regulated heating pad and heating lamp were used 
to maintain a rectal temperature of 37±0.5
oC. Animals were 
randomly divided into treatment groups. Animals allocated to 
the sham group underwent an identical procedure to those of 
the other experimental group, with the exception of MCAO. 
Treatment with SNMC
SNMC (Minophagen pharmaceutical Co., Tokyo, Japan) 
was administered intravenously at various doses. One am-
poule (20 ml) of SNMC contains 40 mg of glycyrrhizin, 20 mg 
of L-cystein, and 400 mg of glycine in physiologic solution. 
Th   e solution concentrations were adjusted with PBS to allow 
an injected volume of 0.5 ml. Glycyrhizin (Sigma, St. Louis, 
MO, USA) was administered intravenously in distilled water 
at various concentrations.
Modifi  ed neurological defi  cit severity scores
Neurological deficits were evaluated using modified 
Neurological Severity Scores (mNSS) at 2 day post-MCAO. 
The mNSS system consists of motor, sensory, balance, and 
re  flex tests, all of which are graded using a scale of 0 to 18 
(normal, 0; maximal deficit, 18) [14]. Motor scores were 
determined by summing the results of two tests. Th  e  fi  rst in-
volved suspending a rat by its tail and allocating scores of zero 
or one to each of the following; flexion of forelimb, flexion 
of hindlimb, and head movement by >10
o with respect to 
the vertical axis within 30 seconds. Th   e second test involved 
placing a rat on the floor and allocating scores as follows: 0 
for normal walking, 1 for an inability to walk straight, 2 for 
circling toward the paretic side, 3 for falling on the paretic Anat Cell Biol 2011;44:304-313 Seung-Woo Kim, et al 306
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side. Sensory tests included a placing test (score, 0-1) and a 
proprioceptive test (score, 0-1). A beam balance test was used 
to test balance and scores of 0 to 6 were allocated as follows: 
0 for balanced with a steady posture, 1 for grasping the side 
of the beam, 2 for hugging the beam with one limb falling 
from the beam, 3 for hugging the beam with two limbs falling 
from the beam or spinning on the beam for over 60 seconds, 
4 for attempting to balance on the beam but falling off   within 
20 to 40 seconds, 5 for attempting to balance on the beam 
but falling off   within 20 seconds, 6 for making no attempt to 
balance or hang on to the beam. Reflex testing scores were 
determined by awarding scores to the following four items 
(total score, 0-4): pinna refl  ex, 0-1; corneal refl  ex, 0-1; startle 
refl  ex, 0-1; seizures, myoclonus or myodystony, 0-1.
Rota-rod test
Twenty-four hours before MCAO, rats were conditioned 
on a rota-rod unit at a constant 3 rpm until they were able to 
remain on the rotating spindle for 180 seconds. One day post-
MCAO, each rat was subjected to test trial on the rota-rod at 
5 rpm. Subsequently, the residence times on the rota-rod at 
10 and 15 rpm were measured with 1 hour intervals between 
trials. Th   is test was repeated at 2 days post-MCAO.
 
Infarct volume assessment
Rats were decapitated at 2 days post-MCAO, and their 
whole brains were sectioned coronally into 2-mm brain 
slices using a metallic brain matrix (RBM-40000, ASI, 
Spring  ville, UT, USA). Slices were immediately stained by 
immersing them in 1% 2,3,5-triphenyl tetrazolium chloride   
at 37
oC for 15 minutes and then treating them with 4% 
paraformaldehyde. Infarcted areas were measured using the 
Scion Image program (Frederick, MD, USA). To account 
for cerebral edema and diff  erential shrinkage resulting from 
tissue processing, the areas of ischemic lesions were adjusted 
using corresponding areas in ipsilateral hemispheres by sub-
tracting the areas of ipsilateral hemispheres from those of 
contralateral hemispheres. Infarct volumes were calculated 
(in mm
3) by multiplying the summed section infarct areas by 
section thickness. 
Immunohistochemistry
Brains were fixed with 4% paraformaldehyde by tran-
scar    diac perfusion and post-fi  xed in the same solution over-
night at 4
oC. Brain sections (30 μm) were prepared using a 
vibratome, and immunological staining was performed using 
the method previously described [15]. Th   e primary antibody 
for anti-ionized calcium binding adaptor molecule-1 (Iba-
1; Wako Pure Chemicals, Osaka, Japan) was diluted to 1 : 
500 and antibodies for anti-Mac2 (ABcam, Cambridge, UK) 
and for anti-myeloperoxidase (MPO; Dako Cytomation, 
Glostrup, Denmark) were diluted to 1 : 250. Subsequent to 
washing with PBS containing 0.1% Triton X-100, sections 
were in  cubated with anti-mouse IgG (Vector Laboratories, 
Bur  lin  game, CA, USA) for anti-Mac2, or with anti-rabbit 
IgG (Vector Laboratories) for anti-Iba-1 in PBS for 1 hour 
at room temperature and visualized using the HRP/3,3'-
diaminobenzidine system. All experiments were repeated 
at least three times and representative images are presented. 
Numbers of Mac2- and MPO-positive cells in 0.1 mm
2 
(0.32×0.32 mm) areas were obtained by counting 12 photo-
graphs, four photographs per experiment. 
 
BV2 cell cultures
BV2 cells were grown in Dulbecco’s modifi  ed Eagle’s me-
dium (Gibco, Carlsbad, CA, USA), supplemented with 5% 
fetal bovine serum (Gibco), penicillin and streptomycin 
(Gibco) at 37
oC in a 95% air/5% CO2 humidifi  ed atmosphere. 
Culture media were changed every 2 days. 
NO measurements 
BV2 cells (1×10
5) plated on 24-well plates were treated 
with lipopolysaccharide (LPS; 200 ng/ml) for 24 hours. In 
order to measure the amount of NO produced by microglia, 
100 μl of the conditioned medium was mixed with an equal 
volume of Griess reagent (0.5% sulfanilamide and 0.05% N-1-
naphthylethylenediamine), and incubated for 10 minutes at 
room temperature. Absorbances were measured at 550 nm 
using a microplate reader. 
RNA preparation and reverse transcription polyme-
rase chain reaction (RT-PCR)
Total RNA was prepared using a TRIzol reagent (Gi-
bco BRL, Gaithersburg, MD, USA) and 1 μg RNA sam-
ples were used for cDNA synthesis using a RT-PCR kit 
(Ro  che, Mannheim, Germany). Changes in the RNA le-
vels of the proinflammatory markers, cyclooxygenase 2 
(COX-2), and inducible NO syntase (iNOS), in the pre  sence 
or absence of SNMC were examined at 24 hours after 
LPS treatment The following primers sets were used: 5'- 
GCTTCAAACAGTTTCTCTACAACAA-3' (forward) and 
5'-CATTTCTTCCCCCAGCAAC-3' (reverse) for COX-2; Neuroprotection by glycyrrhizin-containing SNMC 
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5'-AGAAGGTGGTGAAGCAGGCATC-3' (forward) and 
5'-CGAAGGTGGAAGAGTGGGAGTTG-3' (reverse) for 
glyceraldehydes 3-phosphate dehydrogenase (GAPDH). 
Statistical analysis
Statistical analysis of the data was performed via analysis of 
variance (ANOVA), followed by the Newman-Keuls test. All 
data are presented as means±SEMs and statistical diff  erence 
was accepted at the 5% level.
Results
SNMC suppressed infarct formation in the posti  sche-
mic brain 
To investigate the neuroprotective eff  ects of SNMC in cere-
bral ischemia, SNMC was administered intravenously (i.v.) 
at 1 ml/kg at 30 minutes before or 30 minutes, 3 hours, and 6 
hours post-MCAO (60 minutes) and mean infarct volumes 
were assessed at 2 days post-MCAO. SNMC 1 ml/kg, which 
contains 2 mg/kg glycyrrhizin, is within the accepted dose 
range for the treatment of patients with chronic hepatic 
disease [5, 6]. The administrations of SNMC at 30 minutes 
before MCAO was shown to reduce mean infarct volumes 
to 27.0±4.2% of that of untreated controls (Fig. 1A, B). The 
administration of 1 ml/kg SNMC at 30 minutes or 3 hours 
post-MCAO was shown to reduce mean infarct volumes 
to 37.1±12.4% and 67.8±5.8% of that of untreated controls, 
respectively (Fig. 1A, B). These results indicate that SNMC 
exerts a neuroprotective effect on the postischemic brain, 
markedly reducing infarct volume. To compare the protective 
efficacy of SNMC with that of glycyrrhizin (2 mg/ml), the 
main ingredient of SNMC, infarct volumes of 2 or 5 mg/kg 
pure glycyrrhizin-treated test subjects were compared to those 
of subjects treated with 1 or 2.5 ml/kg of SNMC containing 
an equivalent amount, 2 or 5 mg/kg, of glycyrrhizin. Results 
Fig. 1. Th   e neuroprotective eff  ects of glycyrrhizin in the postischemic brain. (A, B) Stronger Neo-Minophagen C (SNMC, 1 ml/kg) was admini-
stered intravenously at 30 min before or 30 min, 3 h, or 6 h aft  er middle cerebral artery occlusion (MCAO) (60 min). (C, D) SNMC (1 or 2.5 ml/
kg) or glycyrrhizin (2 or 5 mg/kg) was administered intravenously at 3 h aft  er MCAO (60 min). (A, C) Representative images of infarctions in 
coronal brain sections are presented. (B, D) Mean infarction volumes were assessed at 2 days post-MCAO by 2,3,5-triphenyl tetrazolium chlorid 
(TTC) staining, and are presented as means±SEM (n=4-6). *P<0.05, 
†P<0.01. Anat Cell Biol 2011;44:304-313 Seung-Woo Kim, et al 308
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indicates that SNMC reduced infarct more effi   ciently than the 
same amount of pure glycyrrhizin (Fig. 1C, D).
SNMC improved motor impairment and neurological 
defi  cits aft  er MCAO
When SNMC (1 mg/kg) was administered at 30 minutes 
before or 30 minutes, 3 hours, and 6 hours post-MCAO, the 
mean mNSS at 2 days post-MCAO were 5.2±0.3, and 5.2±0.3, 
8.5±0.6 respectively. Th   ese were signifi  cantly lower than that 
of the untreated MCAO group (11.0±0.5) (Fig. 2A). Motor 
activities were assessed using the rota-rod test at a speed of 5 
rpm. Mean time spent on the rota-rod by untreated control 
animals at 2 days post-MCAO was 39.0±5.3 seconds (Fig. 2B), 
and this was markedly extended to 180.0±0, 180.0±0, and 
75.3±22.3 seconds by SNMC administration at 30 minutes 
before or 30 minutes and 3 hours post-MCAO, respectively 
(Fig. 2B). In addition, scores obtained from repeated tests 
at 10 rpm and 15 rpm (with a 1 hour interval between tests) 
showed notably better motor skills for SNMC-treated animals 
(Fig. 2B). These results show that SNMC mitigated motor 
impairment and neurological defi  cits. As evidenced by mNSS, 
neurological defi  cits were less pronounced in SNMC (1 or 2.5 
ml/kg)-treated animals (8.5±0.6 and 6.7±0.6, respectively), 
compared to those of an equivalent amount (2 or 5 mg/
Fig. 2. Recovery of motor defi  cit by Stronger Neo-Minophagen C (SNMC). (A) SNMC (1 ml/kg) was administered at 30 min before or 30 min, 
3 h, or 6 h post-middle cerebral artery occlusion (MCAO) and neurological defi  cits were evaluated using modifi  ed neurological severity scores at 2 
days post-MCAO. mNSS, modifi  ed Neurological Severity Scores. (B) Th  e  rota-rod test was performed at 5, 10 and 15 rpm at 2 days post-MCAO. 
(C) SNMC (1 or 2.5 ml/kg) or glycyrrhizin (2 or 5 mg/kg) was administered at 3 h aft  er MCAO and neurological defi  cits were evaluated using 
modifi  ed neurological severity scores at 2 days post-MCAO. Sham, sham-operated group; MCAO, saline-treated MCAO group; MCAO+SNMC, 
SNMC-administered MCAO group, MCAO+glycyrrhizin, glycyrrhizin-administered MCAO group. Data are presented as means±SEM (n=6-9). 
*P<0.05, 
†P<0.01.Neuroprotection by glycyrrhizin-containing SNMC 
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kg) of glycyrrhizin-treated animals (13.1±1.0 and 8.7±1.1, 
respectively) (Fig. 2C). Th   is corroborates the results obtained 
from infarct volume assessment (Fig. 1C, D). 
 
SNMC suppressed the inflammatory process in the 
posti schemic  brain
We examined whether SNMC exerts an anti-infl  ammatory 
function in the postischemic brain. Brain sections were 
prepared 2 days aft  er reperfusion, and stained with antibody 
against Iba-1 (a marker of cells of myeloid origin) [16], Mac2 
(a marker of activated resident microglia) [17], and MPO (a 
neutrophil marker). In sham-operated control animals, Iba-1
+ 
cells were detected throughout the brain, in which Iba-1
+ cells 
exhibited ramifi  ed morphology (Fig. 3A). In contrast, in the 
postischemic brain, Iba-1
+ cells displayed a round shape with 
a few thick processes, indicative of the activated or phagocytic 
state (Fig. 3B). However, in SNMC-treated animals (1 ml/kg, 
3 hours post-treatment), Iba-1
+ cells displayed an inactivated 
(ramifi  ed) morphology similar to sham-operated animals (Fig. 
3C). In contrast to Iba-1, Mac2
+ and MPO
+ cells were barely 
detected in sham-operated control animals (Fig. 3D, H). At 
1 day aft  er MCAO, Mac2
+ and MPO
+ cells were detected in 
the striatum of ischemic hemispheres (data not shown). At 
2 days post-MCAO, the numbers of Mac2
+ and MPO
+ cells 
showed a marked increase in the infarction core of ischemic 
hemispheres (Fig. 3E, G, I, K). Th   e number of Mac2
+ cells was 
signifi  cantly decreased in 1 ml/kg SNMC-treated animals (Fig. 
3F, G). Similarly, almost no MPO
+ cells were observed in the 
Fig. 3. Suppression of infl  ammation by Stronger Neo-Minophagen C (SNMC) in the postischemic brain. Brain sections were obtained 2 days 
aft  er a sham procedure (A, D, H) or middle cerebral artery occlusion (MCAO) (B, C, E, F, I, J), and immunostained for ionized calcium binding 
adaptor molecule-1 (Iba-1) (A-C), Mac2 (D-F), or myeloperoxidase (MPO) (H-J). SNMC (1 ml/kg) was administered 3 h post-MCAO (C, 
F, J). Representative pictures from three independent experiments are presented. Th   e insets in (A-J) are high magnifi  cation photographs of the 
indicated region (*in each photograph). (G, K) Mac2- and MPO-positive cells in regions (0.1 mm
2) around indicated regions in (D-F) and (H-J), 
respectively, were counted and results are presented as means±SEM (n=12 from 3 animals). Scale bars=1 mm (A-F, H-J), 200 μm (A-F, H-J, inset). 
†P<0.01.Anat Cell Biol 2011;44:304-313 Seung-Woo Kim, et al 310
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brains of SNMC-treated animals (Fig. 3J, K). These results 
indicate that SNMC suppressed microglial activation and 
neutrophil infi  ltration in the postischemic brain. 
SNMC suppressed the LPS-induced activation of 
microglial cells
To verify that the anti-inflammatory effects of SNMC is 
produced directly rather than indirectly, SNMC-dependent 
suppression of microglial activation was examined in LPS- 
treated BV2 cells, a microglia cell line. The cells were sti-
mulated with LPS (0.2 μg/ml) for 24 hours with and without 
SNMC pre-treatment (for 1 hour) or SNMC co-treatment, 
and nitrite production was measured. SNMC pre-treatment 
reduced LPS-induced nitrite production, wherein treatment 
of SNMC (411.3 μl/ml), which generates 1,000 μM of 
glycyrrhizin concentration in the culture media, suppressed 
nitrite production to 29.8±7.2% of the untreated control 
(Fig. 4A). SNMC co-treatment reduced LPS-induced nitrite 
production more effi   ciently and in a dose-dependent manner; 
maximum inhibition (15.6±9.3%) was achieved with 411.3 μl/
ml SNMC treatment (Fig. 4B). In addition, SNMC achieved 
dose-dependent repression of proinflammatory cytokine 
inductions, COX-2 and iNOS, in LPS-treated BV2 cells (Fig. 
4C). These results indicate that SNMC suppressed the LPS-
induced activation of microglial cells. In all experiments, 
SNMC appeared to be more effi   cient at such suppression that 
an equivalent dose of glycyrrhizin (Fig. 4). 
Discussion 
In Japan, SNMC has been used as a treatment for chronic 
hepatitis for more than 30 years. In a multicenter double-
blind study, alanine aminotransferase (ALT) levels in serum 
have been shown to signifi  cantly decrease in patients received 
40 ml/day of SNMC for four weeks (P<0.001) [5, 18]. Further, 
when 100 ml/day SNMC was administered for eight weeks, in 
addition to the improved ALT levels, liver histology showed 
improvement in patients with chronic hepatitis, and liver 
cirrhosis and HCC development occurred less frequently [6, 
18]. Th   ese results indicate that SNMC, in particular, a long-
term treatment, prevents the development of HCC in patients 
with chronic hepatitis. In the present study, we examined 
the protective eff  ect of SNMC in the postischemic brain at a 
dosage of 1 ml/kg, which is within the range of 40-80 ml of 
SNMC treated daily for human patients with chronic liver 
Fig. 4. Anti-inflammatory effects of Stronger Neo-Minophagen C 
(SNMC) in activated microglia. (A, B) Nitrite production was used 
as a surrogate of NO. BV2 cells (1×10
5 cells/well) were pre-treated 
with SNMC at the doses generating 50, 100, 250, 500, or 1,000 μM 
of glycyrrhizin final concentration in culture media for 1 h and then 
treated with lipopolysaccharide (LPS) for 24 h (A). BV2 cells (1×10
5 
cells/well) were treated with SNMC at the doses mentioned above in 
(A) along with 200 ng/ml of LPS for 24 h (B). Changes in nitrite levels 
are presented as means±SEMs (n=4). *P<0.01. To compare the anti-
infl  ammatory potency, 500 or 1,000 μM of pure glycyrrhizin was pre-
treated or co-treated with LPS and nitrite production was measured 
(A, B). (C) Proinflammatory cytokine production was determined 
by reverse transcription polymerase chain reaction 24 h aft  er treating 
LPS (200 ng/ml) in the presence or absence of SNMC (generating 
final concentration of 250 or 500 μM glycyrrhizin in culture media) 
or of 500 μM of pure glycyrrhizin. iNOS, inducible NO syntase; 
COX-2, cyclooxygenase 2; GAPDH, glyceraldehydes 3-phosphate 
dehydrogenase.Neuroprotection by glycyrrhizin-containing SNMC 
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disease. More importantly, we administered a single bolus 
administration, instead of daily treatment for four or eight 
weeks, which strongly suggests that SNMC is indeed a potent 
neuroprotectant in the postischemic brain. Th  e  demonstrated 
marked suppression of infarct formation by 2.5 ml/kg of 
SNMC (Fig. 1C, D) further supports this notion.  
The protective effects of SNMC have been attributed to 
various molecular mechanisms. Th  e  anti-infl  ammatory eff  ect 
of SNMC was thought to be derived from the protective eff  ect 
on the hepatic cellular membrane, for example, preventing 
lysis of hepatocytic membrane and subsequent enzyme leak-
ages [19, 20]. Accumulating evidence points to anti-aller  gic, 
anti-inflammatory, anti-oxidative, and hepatocyte pro-
liferation inducing eff  ects as the underlying molecular eff  ects 
of liver protection of SNMC in liver disease [21-25]. It has 
long been known that glycyrrhizin, a major active ingredient 
of SNMC, exhibits anti-oxidative effects by inhibiting 11β- 
hydroxysteroid dehydrogenase, which converts active cor-
ti    co  sterone (B) to inactive 11-dehydrocorticosterone and 
protects the nonselective mineralocorticoid receptor from 
glucocorticoid excess [26]. Recently, the anti-oxidant eff  ect of 
glycyrrhizin has been reported in H5N1 influenza A virus-
infected cells, wherein ROS formation and redox-sensitive 
signaling (nuclear factor-kB [NF-kB], Jun N-terminal kinase, 
and p38 mitogen-activated protein kinase) are inhibited, 
leading to subsequent inhibition of virus replication and 
pro-inflammatory gene expression [4]. In the brain, NF-
kB inhibition has been reported as a molecular mechanism 
underlying the protective eff  ects of glycyrrhizin on N-methyl-
D-aspartate (NMDA)-induced excitotoxicity in primary 
neurons [27]. 
Recently, increasing amounts of evidence indicate that 
binding to and inhibition of cytokine-like activity of HMGB1 
is a molecular mechanism underlying the protective effects 
of glycyrrhizin [28]. HMGB1 acts as an endogenous danger 
signal, and as such, it has attracted considerable research 
interest. When released extracellularly, HMGB1 serves as a 
danger signal that evokes infl  ammatory reactions by activa-
ting various immune-related cells, including microglia in 
the case of the brain [13, 29, 30]. Intracerebral hemorrhage-
induced injury is significantly attenuated by glycyrrhizin 
via inhibiting HMGB1 [31]. Ogiku et al. [32] reported that 
glycyrrhizin prevents liver injury by inhibiting HMGB1 
production by Kupff  er cells aft  er ischemia-reperfusion injury. 
Recently, a robust neuroprotective eff  ect of glycyrrhizin in the 
postischemic brain has been reported. Th   is might be derived 
from the inhibition of HMGB1 secretion from activated 
microglia due to inhibition of HMGB1 phosphorylation 
via direct binding between HMGB1 and glycyrrhizin [33]. 
Although, the present study demonstrates the anti-inflam-
matory eff  ect of SNMC, further studies regarding inhibition 
of HMGB1 production and secretion are necessary. 
Results showed that the neuroprotective potency of SNMC 
was higher than the equivalent dose of pure glycyrrhizin (Figs. 
1C, D, 4). Th   is may be due to the two amino acids, cystein and 
glycine present in SNMC, which might function to reduce 
the side effects of glycyrrhizin and to stabilize it. Regarding 
this, Sakata et al. [34] reported that L-cystein localized in 
SNMC increases the reduced albumin fraction, which exerts 
higher anti-oxidative eff  ects, and decreases oxidized albumin 
fraction, in human serum albumin preparations. Th  e  reason 
why SNMC is more eff  ective than pure glycyrrhzin, including 
the importance of the two amino acids mentioned above, 
requires further study. 
Th   e remarkably effi   cient infarct suppression was observed 
when glycyrrhizin was pretreated in MCAO animal models 
(Fig. 1A, B). This suggests that in addition to its protracted 
anti-inflammatory effects, SNMC also acts to protect the 
brain from acute damage processes. Excitotoxicity and Zn
+2-
toxicity are responsible for acute and massive neuronal 
death in the ischemic core of the postischemic brain [1]. In 
this regard, the eff  ects of SNMC in NMDA- or Zn
2+-treated 
neurons and underlying mechanisms, including the HMGB1-
dependent mechanism, need further study. Thus, it appears 
that the remarkable protective effects of glycyrrhizin in the 
postischemic brain appear to involve multiple mechanisms, 
which contribute to the alleviation of various aspects of brain 
pathology. 
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